|
|
|
Vol. 12, No. 11, pp. 1599-1609, June 1, 1998
1 Division of Molecular Genetics and 2 Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 4 Institut National de la Santé et de la Recherche Médicale (INSERM) U450, Affiliée Centre National de la Recherche Scientifique (CNRS), Paris, France
| |
Abstract |
|---|
|
|
|---|
Hemizygosity for the retinoblastoma gene RB in man
strongly predisposes to retinoblastoma. In the mouse, however,
Rb hemizygosity leaves the retina normal, whereas in
Rb
/
chimeras pRb-deficient
retinoblasts undergo apoptosis. To test whether concomitant
inactivation of the Rb-related gene p107 is required to
unleash the oncogenic potential of pRb deficiency in the mouse retina,
we inactivated both Rb and p107 by homologous recombination in embryonic stem cells and generated chimeric mice. Retinoblastomas were found in five out of seven adult
pRb/p107-deficient chimeras. The retinal tumors showed
amacrine cell differentiation, and therefore originated from cells
committed to the inner but not the outer nuclear layer. Retinal lesions
were already observed at embryonic day 17.5. At this stage, the
primitive nuclear layer exhibited severe dysplasia, including
rosette-like arrangements, and apoptosis. These findings provide formal
proof for the role of loss of Rb in retinoblastoma development
in the mouse and the first in vivo evidence that p107 can exert
a tumor suppressor function.
[Key Words: Retinoblastoma; apoptosis; Rb; p107; tumor suppressor gene; chimeric mice]
| |
Introduction |
|---|
|
|
|---|
Hereditary retinoblastoma, a childhood tumor of the eye, has
served as a paradigm for studies concerning the role of tumor suppressor genes in cancer predisposition. The
rate-limiting step in the initiation of both the hereditary and
sporadic form of this tumor is loss of function of the retinoblastoma
gene RB in the developing retina. Inheritance of one mutant
RB allele not only predisposes to retinoblastoma (90%) early
in life but also to osteosarcomas (2%) later on (Draper et al. 1986
;
Friend et al. 1987
). In addition, loss of function of RB has
been frequently found in lung, breast, and bladder carcinomas (Harbour
et al. 1988
; Lee et al. 1988
; Horowitz et al. 1990
). Also, upstream
regulators of pRB are repeatedly found mutated (p16 and CDK4) or
overexpressed (cyclin D1) in human tumors (Hall and Peters 1996
). Thus,
deregulation of pRB function appears to be a common event in the
development of many tumor types.
pRB plays an important role during the G1 phase of the cell
cycle, when cells are responsive to extracellular positive and negative
proliferation signals (Sherr 1994
). pRB functions in a pathway that
transduces such signals to the cell nucleus modulating the activity of,
for example, E2F transcription factors. In G1, the
transactivating potential of these proteins is suppressed by their
association with hypophosphorylated pRB. The E2Fs are released upon
phosphorylation of pRB by cyclin D-dependent kinases whose activity
depends on mitogenic stimuli. After passing a restriction point, pRB
stays in the hyperphosphorylated, inactive conformation throughout the
autonomous program that carries the cell through the remaining of
G1, S, and G2 phases of the cell cycle (Weinberg 1995
). In both sequence and function pRB is closely related to two
other nuclear phosphoproteins, p107 and p130 (Ewen et al. 1991
; Hannon
et al. 1993
; Li et al. 1993
; Mayol et al. 1993
). Extensive structural
homology is found in their so called pocket domain, the binding site
for many viral oncoproteins, including adenovirus E1A, simian virus 40 large T antigen, and human papillomavirus E7 (DeCaprio et al. 1988
;
Whyte et al. 1988
; Dyson et al. 1989
). Like pRB, p107 and p130 may also
act as negative regulators of cell proliferation through interaction
with E2F transcription factors (Zhu et al. 1993
; Claudio et al. 1994
;
Qin et al. 1995
). However, different pRB family proteins associate with
different E2Fs at different times during the cell cycle (Bernards
1997
). In mice, the Rb gene family members share a wide
expression pattern, with high and overlapping expression of Rb
and p107 in embryonic liver and CNS (Jiang et al. 1997
).
Retinoblastomas have not been described to occur spontaneously in
species other than man. In addition to loss of RB, a limited number of karyotypic rearrangements with unknown functional
significance have been found in retinal tumors (Kusnetsova et al. 1982
;
Squire et al. 1984
). In the mouse, hemizygosity for Rb does
not lead to retinoblastoma. Instead, Rb+/
mice succumb to pituitary gland tumors from 6-8 months on.
Rb
/
embryos show severe
defects in central neurogenesis, fetal liver erythropoiesis, lens
development, and myogenesis, and die around days 12-15 of gestation
when the developing retina appears normal (Clarke et al. 1992
; Jacks et
al. 1992
; Lee et al. 1992
; Morgenbesser et al. 1994
; Robanus Maandag et
al. 1994
; Williams et al. 1994b
; Zacksenhaus et al. 1996
). However,
evidence for a function of pRb at later stages of retinal development
has come from the analysis of chimeric
Rb
/
mice. Apoptosis was
observed in the developing retina beyond day 16 of gestation and the
number of Rb
/
cells in the
adult retina was significantly reduced (Robanus Maandag et al. 1994
).
These observations suggest that in the mouse loss of Rb during
development of the retina results in cell death rather than enhanced
cell proliferation. Therefore, additional mutations may be required to
unleash the oncogenic potential of pRb deficiency in mouse
retinoblasts. This hypothesis is supported by the analyses of various
transgenic and knock-out mouse lines. Retinoblastomas develop in
transgenic mice with retina-specific expression [using the human
interphotoreceptor retinoid-binding protein (IRBP) promoter] of SV40
Tag or HPV-16 E7, the latter exclusively in a
p53
/
background (Al-Ubaidi et
al. 1992
; Howes et al. 1994
). These results suggest a requirement for
multiple inactivations that possibly include one or more of the pocket
proteins and p53. However, which specific proteins need to be
inactivated has not been answered and the oncoproteins may elicit other
oncogenic alterations as well. In addition, the use of specific
promoters to drive SV40 Tag or HPV-16 E7 limits inactivation to those
cells in which the oncoproteins are expressed. As a consequence,
analyses have remained restricted to a subset of cells within a
specific differentiation window characterized by expression of
IRBP. Knockout mouse models lack these limitations of the
transgenic mouse models. Mice have been generated with (various
combinations of) inactivated candidate genes that may be required for
retinoblastoma development.
Rb+/
;p107
/
mice do not show any altered tumor predisposition when compared with
Rb+/
mice but develop multiple
dysplastic lesions of the retina that are absent in
Rb+/
and
p107
/
mice (Lee et al. 1996
).
In addition, retinal dysplasias have been observed in 40% of the
Rb+/
;p53
/
mice as well as pinealoblastomas that show loss of heterozygosity for
Rb (Williams et al. 1994a
).
The lethality of pRb/p107-deficient embryos at day 11.5 of gestation precludes to study the effect of concomitant pRb and p107
deficiency at later stages of development and during adult life (Lee et
al. 1996
). To circumvent this problem, we investigated the tumorigenic
and developmental potential of
Rb
/
;p107
/
cells in the retina of chimeric mice generated with
Rb
/
; p107
/
embryonic stem cells. We report here that loss of function of both
Rb and p107 in murine retinoblasts leads to
retinoblastoma originating from cells committed to the amacrine cell
compartment of the inner nuclear layer but not from those committed to
the outer nuclear layer of the retina.
| |
Results |
|---|
|
|
|---|
Generation of mutant Rb;p107 chimeras
The p107 gene was inactivated in murine embryonic stem
(ES) cells by homologous recombination. Because p107 is
expressed in ES cells (Fig. 1B), a targeting vector
was constructed with the promoterless IRES
geo
cassette (Mountford et al. 1994
) inserted behind codon 145 of
p107 (Fig. 1A). Homologous recombination of the p107
targeting vector with mouse genomic DNA was predicted to produce a
p107 null allele caused by an in-frame termination codon in
the IRES sequence. On introduction of the p107 targeting vector into strain 129/Ola-derived ES cells homologous
recombinants were obtained with a frequency of 65%. One of these
clones carried IRES
geo in both p107
alleles giving a p107
/
ES cell
line. To confirm full inactivation of p107, the level of p107
protein was examined in extracts of ES cells. Whereas p107 could be
readily detected in wild-type ES cells, no p107 protein was detected in
p107
/
ES cells by Western blot
analysis using the anti-p107 rabbit antibody C-18 (Fig. 1B).
|
Subsequently, in this p107
/
ES
cell line both alleles of the retinoblastoma gene Rb were
inactivated by two rounds of homologous recombination with the isogenic
targeting vectors 129Rb-hyg (Te Riele et al. 1992
) and 129Rb-his. These
vectors carry the hygromycin and histidinol resistance genes,
respectively, inserted into exon 19 of Rb, which on homologous
recombination lead to Rb null alleles (Clarke et al. 1992
).
In an attempt to investigate the effect of combined loss of Rb,
p107, and p53 in the retina, we also introduced into
Rb
/
;p107
/
ES cells the dominant-negative p53 mutant minigene p53DD
(Shaulian et al. 1992
) driven by the 1.3-kb human interphotoreceptor
retinoid-binding protein (hIRBP) promoter fragment (Liou et al. 1990
).
p53DD has been shown to elicit a biological effect corresponding to
genetic loss of p53 including a reduction in apoptosis and acceleration of tumorigenesis (Bowman et al. 1996
). We expected
Rb
/
;p107
/
;hIRBPp53DD chimeras to mimic
hIRBP-E7;p53
/
transgenic mice,
which developed retinoblastoma (Howes et al. 1994
). Multiple copies of
hIRBPp53DD were introduced into
Rb
/
;p107
/
ES cells by coelectroporation with the selection marker PGKpur.
Rb+/
;p107
/
,
Rb
/
;p107
/
, and
Rb
/
;p107
/
;hIRBPp53DD ES cell clones were verified for the correct
karyotype and injected into C57BL/6 blastocysts to generate
chimeras. The level of pigmentation in the retinal pigment epithelium (RPE)
served as a rough indication for the extent of chimerism of the eye
(nonpigmented areas result from ES cell contribution).
Poor chimerism in
Rb
/
;p107
/
chimeras
Chimeric
Rb+/
;p107
/
mice were readily obtained (28/62 births) and were able
to transmit ES cell-derived alleles through the germ line. In
6/56 chimeric eyes, the retina showed some dysplasia. For
example, Figure 2A shows a small lesion in the transition region of the
inner nuclear to the outer plexiform layer. In contrast, Rb
/
;p107
/
chimeras were obtained with low efficiency (7/56 births)
and only when a low number of ES cells (4-6) per blastocyst was
injected. In general, the ES cell contribution in the tissue samples of these animals was reduced twofold with respect to that of
Rb
/
chimeras (Robanus Maandag
et al. 1994
) (not shown).
|
Retinoblastoma in
Rb
/
;p107
/
chimeras
Retinoblastomas were found in five of seven
Rb
/
; p107
/
(;hIRBPp53DD) chimeras: Two of six eyes in
Rb
/
;p107
/
and four of eight eyes (one bilateral case) in
Rb
/
;p107
/
;hIRBPp53DD chimeras. Histological examination of the eyes of Rb
/
;p107
/
chimeras revealed in a 1-month-old chimera a developing retinal tumor
between the photoreceptor layer and the RPE, consisting of
inner-nuclear-layer-like cells (Fig. 2B). In a chimera of 3.5 months,
one of the eyes contained a large tumor process. Microscopically, this
appeared to be a retinoblastoma that had invaded into the anterior eye
chamber (Fig. 2C,D). The tumor cells often formed small irregular
circles. Also, invasion of tumor cells into the outer nuclear layer
apparently induced the rearrangement of normal photoreceptor cells into
rosettes (Fig. 2D). In a chimeric
Rb
/
;p107
/
;hIRBPp53DD
mouse of postnatal day 15 (P15) we observed a malignant nodular growth
of inner-nuclear-layer-like cells at multiple regions (Fig. 2E,F);
similar to the tumor in Figure 2B, the tumor cells tended to invade
between the photoreceptor layer and RPE (Fig. 2F). We found three large
tumors in chimeric
Rb
/
;p107
/
;hIRBPp53DD
mice of 2.5 (Fig. 2G,H) and 4 months. In the four large tumors, 3-10
mitotic figures were counted per high power field with a 40×
objective (not shown). Thus, both types of chimeras developed
retinoblastoma with similar incidence (although the numbers were
small), inner-nuclear-layer-like appearance, and tendency to grow
between the photoreceptor layer and RPE.
To investigate whether the tumors were ES cell-derived, tumor cells were scraped from formalin-fixed, paraffin-embedded tissue sections, DNAs were isolated and subjected to simple sequence repeat (SSR) analysis. PCR amplification of a polymorphic SSR marker on chromosome 2 (D2mit94) showed that the four large tumors that could be tested in this way were of ES cell origin (Fig. 3). These results indicate that loss of function of both Rb and p107 leads to retinoblastoma in the mouse.
|
Retinoblastoma has characteristics of the inner nuclear layer
Our results suggested that the hIRBPp53DD transgene had
not contributed to tumorigenesis. To address this point, we further characterized the tumors by immunohistochemistry. Staining with an
anti-p53 antibody of the retina of a control hIRBPp53DD
transgenic mouse identified a compartment of
non-IRBP-expressing cells in the inner nuclear layer (Fig. 4B,
left). These cells were positively identified with
anti-syntaxin that labels neuronal amacrine cells in the inner nuclear
layer and their synaptic processes in the inner plexiform layer
(Barnstable et al. 1985
) (Fig. 4A, left). None of the tumors in
Rb
/
;p107
/
;hIRBPp53DD
chimeras expressed the p53DD transgene (Fig. 4B, right). This
indicates that they did not express IRBP, as was confirmed by
staining with an anti-IRBP antibody recognizing the outer segments of
photoreceptor cells (Carter-Dawson et al. 1986
) (Fig. 4C). Instead, all
retinal tumors showed extensive positive staining with anti-syntaxin
(Fig. 4A, right). Furthermore, the tumors were positive with an
antibody against neuron-specific enolase (NSE), labeling all neuronal
cells of the retina (Schmechel et al. 1978
) (Fig. 4E), but negative for
the antibody against 200-kD neurofilament protein (NF200kd) which
identifies the nerve fibers of the ganglion cells and axonless
horizontal cells (Drager et al. 1984
) (Fig. 4F). Some staining in the
tumors was found with an antibody against glial fibrillary acidic
protein (GFAP) (Fig. 4D), which recognizes glial cells, that is,
retinal astrocytes in the ganglion cell layer and shows some positivity
in the outer plexiform layer (Bjorklund et al. 1985
). Double staining
with anti-syntaxin and anti-GFAP showed that the cell bodies labeled by
anti-syntaxin did not coincide with those labeled by anti-GFAP,
indicating that the tumors contained two different cell types, neuronal
amacrine and glial cells (Fig. 4G,H). The abnormally high GFAP staining
in the adjacent retina may be indicative of reactive Müller
cells, which express increased levels of GFAP under pathogenic
conditions (Eisenfeld et al. 1984
) (Fig. 4I; see also Fig. 4D, right).
|
Taken together, these results show that the tumors largely originated from cells committed to the amacrine cell compartment of the inner nuclear layer.
The majority of
Rb
/
;p107
/
retinoblasts do not form tumors but undergo apoptosis
During normal retinal development, the
non-IRBP-expressing amacrine and ganglion cell compartments
are formed prenatally, the Müller cell compartment postnatally.
Also prenatally, IRBP-expressing cells begin to appear which
will ultimately constitute the outer nuclear layer (photoreceptor cell
compartment) and the outer part of the inner nuclear layer (bipolar and
horizontal cell compartment) (Young 1985
; Al-Ubaidi et al. 1992
). Our
results suggest that the tumors originate prenatally from a retinoblast
population committed to form amacrine cells, but not from the
population committed to form IRBP-expressing cells (Duke-Elder
and Cook 1963
). To identify early stages of tumor development and to
study the fate of pRb/p107-deficient
IRBP-expressing cells, we analyzed chimeric eyes at various
stages of retinal development.
Whereas only a limited number of chimeras survived into adulthood, at
day 17.5 of gestation chimeric
Rb
/
; p107
/
(;hIRBPp53DD)
embryos were present at normal frequency and often showed a high
contribution of ES cells to the RPE. At this stage of development,
11/23 chimeric eyes already showed severe dysplasia, rosette-like arrangements and many pyknotic nuclei, indicative of
apoptotic cell death (Fig. 5B-D), this in contrast
to 6/6 normal chimeric
Rb+/
;p107
/
retinas of the same age (Fig. 5A). Clear anti-p53DD antibody staining
in the ventricular layer of the developing retina identified Rb
/
; p107
/
;hIRBPp53DD
retinoblasts that had apparently reached the differentiation stage of
IRBP-expressing cells (Fig. 6B). These cells
were virtually absent at P15, even at retinal regions that were highly
chimeric as deduced from the presence of malignant nodular growths of
the inner nuclear layer (Fig. 6C, see also Fig. 4B). Apparently,
pRb/p107-deficient cells can contribute to the
IRBP-expressing compartment, but are excluded from the retina
between E17.5 and P15. Indeed, apoptotic cell death in chimeric
Rb
/
;p107
/
retinas could be detected as early as day 17.5 of gestation and continued at least until P11 (Fig. 7B,D).
|
|
|
These results allow us to draw two conclusions. Firstly, oncogenic transformation of pRb/p107-deficient retinoblasts occurs as early as day 17.5 of gestation and involves cells committed to the non-IRBP-expressing amacrine cell compartment of the inner nuclear layer. Secondly, pRb/p107-deficient cells can contribute to the IRBP-expressing compartment, but these cells do not grow out to retinoblastoma. Instead, they undergo apoptosis before P15, likely at the stage of differentiation to mature bipolar, horizontal, and photoreceptor cells.
| |
Discussion |
|---|
|
|
|---|
In contrast to the situation in humans, mice hemizygous for the
retinoblastoma gene Rb do not develop retinoblastoma, but pituitary gland tumors. Also, chimeric
Rb
/
mice do not form
retinoblastomas but, instead, undergo retinal apoptosis during
development. Apparently, the murine retina is better protected against
tumorigenesis than the human retina. For example, in the mouse,
additional mutations may be required for the oncogenic transformation
of pRb-deficient retinoblasts. Indications for this have come from
studies in transgenic mice in which concomitant inactivation of pocket
proteins and p53 by overexpression of HPV-16 E7 (in a p53 null
background) or SV40 Tag led to development of retinoblastoma. However,
these transgenic mouse models do not accurately specify the mutational
requirements for retinal tumorigenesis. On the other hand, the use of
knockout mice carrying specific (combinations of) mutations is limited by the early death of pRb-deficient embryos. Therefore, we generated chimeric mice using ES cells carrying disruptions in both Rb
and p107. This approach permitted us to address the question
whether loss of p107 unleashes the expected oncogenic
potential of loss of Rb in retinoblasts.
Our results clearly demonstrate that this is the case: In the mouse,
loss of function of both Rb and its close relative
p107 leads to retinoblastoma. Although it is generally
believed that loss of pRb function is the key event in retinoblastoma
development in the various transgenic mouse models, proof for this has
been lacking. Here we have provided formal evidence for the role of loss of Rb in the development of retinoblastomas in mice.
Moreover, our results indicate that p107 can act as a tumor
suppressor gene in the mouse. p107 exerts its tumor suppressor function
in a conditional fashion, that is, it suppresses tumorous outgrowth of
pRb-deficient retinoblasts. In the presence of wild-type pRb activity,
hetero- or homozygosity for mutant p107 by itself does not
lead to tumorigenesis (Lee et al. 1996
). Thus, p107 and pRb may
functionally overlap, as was previously suggested by their structural
homology and capacity to block the cell cycle in vitro (Zhu et al.
1993
; Beijersbergen et al. 1995
). Our results provide the first
demonstration of functional synergism of pRb and p107 in controlling
proliferation in vivo. It remains unclear why this safeguard mechanism
does not operate in human retinal cells. It is possible that
p107, in contrast to the situation in the mouse, is not
adequately expressed in the human retina. Alternatively, murine p107
may respond to upstream regulators of pRb, whereas human p107 may not.
The cell of origin of human retinoblastoma is a moot point (Tsokos et
al. 1986
; Nork et al. 1995
). Many believe it is a primitive multipotential cell, but differentiation toward amacrine cells has only
sporadically been found (Albert et al. 1974
; Tarkkanen et al. 1984
;
Tsokos et al. 1986
). Others suggest it is a cell capable of bipotential
differentiation into photoreceptor and glial cells. However, proof for
the neoplastic nature of glial cells in human retinoblastoma is
lacking. Also, the retinoblastoma cell type in the transgenic mouse
models remained largely undefined, although oncogenic transformation
was directed to the IRBP-expressing cell compartment. In our
model system, immunohistochemistry of the tumors revealed two distinct
cell types: Non-IRBP-expressing neuronal amacrine cells
(majority) and glial cells (minority). This may indicate that the
tumors originate from a primitive retinoblast with bipotential
differentiation capacity into amacrine cells and glial cells. The
relatively modest GFAP staining in the tumors may also represent
nontumorigenic, reactive Müller cells that increased
GFAP expression under pathogenic conditions (Eisenfeld et al.
1984
). Such cells may support the malignant outgrowth of amacrine-like
tumor cells. The in situ identification of individual b
/
;p107
/
cells in the chimeras by a marker will further address this issue. Formally, we cannot fully exclude the possibility that the tumors in
our system had originated from IRBP-expressing precursors that were destined to form the photoreceptor cell layer, but had lost this
capacity (and IRBP expression) through oncogenic
transformation and acquired amacrine cell differentiation.
Although the retinal tumors arise at a high frequency in chimeric
Rb
/
;p107
/
(;hIRBPp53DD)
mice, additional mutations may be required. First, some but not all
retinas that were chimeric in the RPE formed retinoblastomas. Second,
Rb+/
;p107
/
mice (Lee et al. 1996
) and chimeric
Rb+/
;p107
/
mice (our data) often showed regions of retinal dysplasia but never
developed a malignant tumor. Third, the tumors apparently arose from
developmental defects that occurred as early as embryonic day 17.5. At
this stage, the primitive nuclear layer showed severe dysplasia but
also extensive apoptosis. This result suggests that in addition to loss
of Rb and p107, a genetic alteration counteracting apoptotic cell death is required for development of retinal tumors. We
cannot exclude, however, that apoptotic cell death only included the
IRBP-expressing pRb/p107-deficient compartment
of the retina (see below). In line with this, we could not obtain
evidence for involvement of p53 mutations in retinoblastoma
development. Single-strand conformation polymorphism and sequence
analyses of p53 exons 5-8 in DNA of the large
Rb
/
;p107
/
tumor did not reveal a p53 mutation (E. Robanus-Maandag and A. Berns, unpubl.). Moreover, none of the tumors immunoreacted with the
anti-p53 antibody.
IRBP-expressing retinoblastomas did not develop in our system.
IRBP-expressing pRb/p107-deficient cells were
present in the ventricular layer of the embryonic retina, however,
these cells underwent massive apoptosis and had completely disappeared
from the developing retina by postnatal day 15. Death of
IRBP-expressing pRb/p107-deficient cells is in
agreement with the observed retinal degeneration in the hIRBP-E7
transgenic mice (Howes et al. 1994
). These authors showed that
hIRBP-driven expression of E7 could give rise to retinoblastoma
exclusively in a p53
/
background, suggesting that p53 counteracted apoptosis of cells that
lacked Rb (and p107) function. Therefore, the absence
of p53DD-expressing retinoblastomas in our chimeric
Rb
/
;p107
/
; hIRBPp53DD
mice was unexpected. It is possible that the wild-type p53 was not
fully inactivated by p53DD. Alternatively, other as yet unknown
oncogenic alterations may be required for the development of outer
nuclear layer tumors. In the
hIRBP-E7;p53
/
transgenic mice,
genetic instability throughout all stages of development may have
provided the required mutation(s) [note that in
hIRBP-E7;p53+/
transgenic mice
no retinal tumors were found (Howes et al. 1994
)]. In conclusion, our
observations show that
Rb
/
;p107
/
retinoblasts committed to the non-IRBP-expressing inner
nuclear layer have the potential to form tumors at high incidence,
whereas IRBP-expressing
Rb
/
;p107
/
retinoblasts do not. Because both types of retinoblasts originate from
the same
Rb
/
;p107
/
retinal stem cell, different, and possibly fewer, mutations may be
required for the development of inner nuclear layer tumors than for the
development of outer nuclear layer tumors.
Functional loss of Rb in murine retinoblasts has been
generally believed as essential for the development of retinoblastoma analogous to the situation in man. However, the absence of
retinoblastoma in Rb+/
and
chimeric Rb
/
mice indicated
that besides loss of function of Rb additional mutations are
required to induce tumorigenesis in the murine retina. Our data
unequivocally demonstrate that the inactivation of both Rb and
the closely related gene p107 leads to oncogenic
transformation of cells committed to the amacrine cell compartment of
the inner nuclear layer but not of cells committed to other retinal
compartments. Thus, p107 can act as a tumor suppressor gene in
the mouse. Finally, our results illustrate that the generation of
chimeric mice with ES cells carrying multiple gene lesions is a valuable tool
to assess the role of these genes in development and tumorigenesis.
| |
Materials and methods |
|---|
|
|
|---|
Marker plasmids
For the disruption of multiple genes in a single cell line, we
generated two new selectable markers: PGKpur and
PGKhis. The Streptomyces alboniger puromycin
phosphotransferase gene pur (Lacalle et al. 1989
; kindly
provided by A. Jimenez) was provided with a Kozak consensus sequence
and inserted between the PGK promoter and poly(A) sequences (McBurney
et al. 1991
), giving PGKpur. The Salmonella
typhimurium histidinol dehydrogenase gene his (Hartman and
Mulligan 1988
) was inserted between the PGK promoter and poly(A) sequences, giving PGKhis.
Generation of DNA fragments for electroporation
For construction of the p107 targeting vector
(129p107-IRES
geo), a 129-derived genomic clone covering a portion
of the mouse p107 gene was isolated using the human
p107 cDNA (kindly provided by M. Ewen and D. Livingston,
Dana-Farber Cancer Institute, Boston, MA) as a probe. An exon was
identified within the genomic clone by a combination of Southern blot
and sequence analysis. Into a unique EcoRV site within this
exon, IRES
geo [derived from the plasmid
pGT1.8IRES-
geo (Mountford et al. 1994
), kindly provided by A. Smith] was inserted, resulting in a fusion transcript containing p107 codons 1-145 and IRES
geo. The
targeting vector was linearized before electroporation into ES cells
(Fig. 1A). Two comparable isogenic targeting vectors for the
Rb locus were used: 129Rb-hyg (Te Riele et al. 1992
) and
129Rb-his, carrying instead of PGKhyg the 2.2-kb
PGKhis fragment. Both markers were inserted into the BglII site of exon 19.
For the construction of hIRBPp53DD the plasmid pSPp53DD
(Shaulian et al. 1992
; kindly provided by M. Oren) was digested with BamHI, filled in with Klenow polymerase, and digested with
EcoRI. The resulting 800-bp p53DD cDNA fragment, containing
amino acids 1-13 and 302-390, was ligated into the
EcoRV-EcoRI-digested plasmid containing the 1.3-kb
hIRBP promoter fragment, kindly provided by G. Liou (Medical College of
Georgia, Augusta). phIRBPp53DD was linearized with
BamHI, pPGKpur with XhoI.
Generation of mutant ES cell clones and chimeric mice
The E14 ES cell line, derived from 129/Ola and
kindly provided by M. Hooper (Western General Hospital, Edinburgh, UK),
was subcloned. Subclone IB10 and its derivatives were grown on feeder layers of
-irradiated murine embryonic fibroblasts in Glasgow modified Eagle medium supplemented with 10% fetal calf serum, 1×
nonessential amino acids, 1 mM sodium pyruvate, 2 mM L-glutamine, 0.1 mM 2-mercaptoethanol,
and 1000 U/ml of ESGRO-LIF. During selection the ES cells
were cultured in BRL-conditioned medium (Hooper et al. 1987
).
129p107-IRES
geo was introduced into IB10 ES cells and
G418-resistant cells were selected as described (Te Riele et al. 1992
). Southern blot analysis with the 5' probe A and 3' probe B,
located as in Figure 1A, of EcoRI-digested DNA from selected
clones showed in case of a homologous recombinant both a band of 20 kb
of the nonmodified p107 locus, and a band of 3.4 and 16.6 kb
of the modified p107 locus, respectively. In addition, one
p107
/
ES cell clone was
obtained that had inserted the promoterless IRES
geo in both p107 alleles.
Subsequently, in this p107
/
ES
cell clone targeting at the Rb locus was performed with
129Rb-hyg as described (Te Riele et al. 1992
). In a resulting
Rb+/
;p107
/
clone the second wild-type Rb allele was targeted with
129Rb-his. One day after electroporation, ES cells were selected for
resistance to 1.5-2.5 mM histidinol for 7 days. Southern
blot analysis with the 5' Rb probe B (Te Riele et al.
1992
) of EcoRI-digested DNA from selected clones showed a
7.2-kb band in case of a correctly recombined 129Rb-his fragment.
The 5.0-kb hIRBPp53DD fragment was coelectroporated with the
4.3-kb PGKpur fragment into
Rb
/
;p107
/
ES cells in a molar ratio of 10:1. One day after electroporation, ES cells were selected for resistance to 1.8 µg/ml
puromycin for 7 days. A 450-bp EcoRV-XbaI fragment
of hIRBPp53DD was used as probe in the Southern blot analysis
of EcoRV-digested DNA from the selected clones. A 5-kb band
indicated a head-to-tail integration of hIRBPp53DD.
Selected ES cell clones were verified for the correct karyotype (>12/15 metaphase chromosome spreads with 40 chromosomes). Chimeric mice were generated by injection of 4-12 ES cells into C57Bl/6 blastocyst stage embryos.
Western blot analysis
ES cells (3 × 106) were resuspended in 50 µl of 2× Laemmli sample buffer. The lysates were boiled for 10 min and, after centrifugation for 2 min, 30% of the supernatant was loaded on a 10% SDS-polyacrylamide gel. After resolution, the gel was transferred to a Protran membrane (Schleicher & Schüll) by electroblotting. For the antibody incubation with anti-p107, performed in 5% Blotto dissolved in TBST (Tris-buffered saline; 0.1% Tween-20), the polyclonal rabbit anti-human antibody C-18 was used that recognizes amino acids 1052-1068 of p107 (Santa Cruz Biotechnology). Subsequently, the membrane was incubated with goat anti-rabbit horseradish peroxidase-labeled antibody. Antigen-antibody complexes were detected by enhanced chemoluminescence (ECL; Amersham).
Generation of transgenic hIRBPp53DD mice
The 2.1-kb ClaI-BamHI fragment of
phIRBPp53DD was microinjected into FVB zygotes. Southern blot
analysis of EcoRV-digested DNA from tail biopsies was
performed as described (Laird et al. 1991
) using the 450-bp
EcoRV-XbaI fragment of phIRBPp53DD as probe.
ES cell contribution in (tumor) tissues
DNA was isolated from tissue samples as described by Laird et al.
(1991)
. The extent of chimerism was determined by detection of the
Rb wild-type and mutated EcoRI fragments with probe A
on Southern blots as described before (Te Riele et al. 1992
) using the
PhosphorImager. Cells of the tumor areas in the unstained 10 µm
tissue sections were scraped off with a scalpel from the plain glass
slides and transferred to 0.5 ml of xylene to dissolve the paraffin for
5 min. One volume of 100% ethanol was mixed with the supernatants and
after 5 min the tissues were pelleted, dried at 55°C, and incubated
in 50 mM Tris (pH 8.5), 1 mM EDTA, 0.5% Tween-20,
and 200 µg/ml proteinase K overnight at 55°C and
for 10 min at 95°C. To determine the percentage of ES cell-derived cells in the tumors, simple sequence repeat analyses were performed on
the DNA solutions with the primer set D2mit94 (Mouse MapPairs, Research
Genetics, Huntsville, AL) as described (Dietrich et al. 1992
).
Histological analysis and immunostaining
Embryos and tissues were fixed in phosphate-buffered formalin, embedded in paraffin, sectioned at 5 µm, and stained with hematoxylin and eosin according to standard procedures.
For immunohistochemical detection of antigens, the rehydrated tissue
sections were boiled for 15 min in citrate buffer at pH 6.0 and cooled
down slowly before preincubation with 1% normal goat serum. The
following primary antibodies were used: (1) mouse monoclonal anti-human
p53 that recognizes amino acids 370-378 (pAb421, Harlow et al. 1981
;
Oncogene Science); (2) mouse monoclonal anti-rat syntaxin (HPC-1, Sigma
Biosciences); (3) rabbit polyclonal anti-bovine IRBP (kindly provided
by Yvonne De Kozak, U450 INSERM, Paris, France); (4) rabbit polyclonal
anti-cow glial fibrillary acidic protein (GFAP; DAKO); (5) rabbit
polyclonal anti-bovine neuron-specific enolase (NSE; Chemicon
International); and (6) rabbit polyclonal anti-bovine neurofilament,
200-kD subunit (NF200kd; Sigma).
Expression of the p53DD transgene was detected by the indirect
immunoperoxidase assay with DAB substrate as described (Ivanyi et al.
1989
). Expression of the endogenous retinal antigens was determined by
the indirect immunofluorescence assay with goat anti-mouse or pig
anti-rabbit FITC (DAKO) and, in case of double staining, goat
anti-rabbit Texas Red (Molecular Probes, Leiden, The Netherlands).
Incorporated fluorescein was detected by confocal laser scan microscopy.
In situ detection of apoptosis
TUNEL analyses (Gavrieli et al. 1992
) were performed on 8-µm
tissue sections as described (In Situ Cell Death Detection kit, Boehringer Mannheim). Incorporated fluorescein was detected by confocal
laser scan microscopy.
| |
Acknowledgments |
|---|
We thank Paul Krimpenfort, Karin van Veen-Buurman, and René Bobeldijk for assistance in zygote and blastocyst injections; Jurjen Bulthuis, Kees de Goeij, Lia Kuijper-Pietersma, and Eva van Muylwijk for histotechnical assistance; Rein Regnerus for tail DNA analysis; Fina van der Ahé, Kwamé Ankama, Nel Bosnie, Halfdan Raasø, Loes Rijswijk, and Auke Zwerver for animal care; Lauran Oomen for assistance with the confocal laser scan microscope; René Bernards, Gabriel Gil-Gómez, and Marc Vooijs for critically reading the manuscript. This work was supported by The Netherlands Organization for Scientific Research (NWO) through a program grant to A.B. (E.R.-M.), the European Community (E.R.-M.), and the Netherlands Cancer Foundation (J.-H.D.).
The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.
| |
Footnotes |
|---|
Received February 20, 1998; revised version accepted April 3, 1998.
3 Present address: Instituto di Neurofisiologia del Consiglio Nazionale Ricerche, Pisa, Italy.
5 Corresponding author.
E-MAIL hriele{at}nki.nl; FAX 31 205121954.
| |
References |
|---|
|
|
|---|